@article{68f280fce7eb470c80bdca6b5b45a3e2,
title = "Potential risks of adjunctive use of atypical antipsychotic drugs for the treatment of depression",
author = "Shinichiro Nakajima and Takefumi Suzuki and Koichiro Watanabe and Haruo Kashima and Hiroyuki Uchida",
note = "Funding Information: Dr. Watanabe has served on the advisory board of Dainippon Sumitomo Pharma, Eli Lilly, Janssen, Otsuka and Schering-Plough and received speaker's honoraria from Asahi Kasei, Astellas, Dainippon Sumitomo, Eli Lilly, GlaxoSmithKline, Janssen, Otsuka , and Pfizer within the past 5 years. Dr. Uchida has received grants from Pfizer and speaker's honoraria or manuscript fees from Dainippon Sumitomo Pharma, GlaxoSmithKline, Jannsen Pharmaceutical , and Otsuka within the past 5 years. Other authors have no financial or other relationship relevant to the subject of this manuscript. Copyright: Copyright 2010 Elsevier B.V., All rights reserved.",
year = "2010",
month = mar,
doi = "10.1016/j.pnpbp.2009.12.023",
language = "English",
volume = "34",
pages = "435--436",
journal = "Progress in Neuro-Psychopharmacology and Biological Psychiatry",
issn = "0278-5846",
publisher = "Elsevier Inc.",
number = "2",
}